Precision Trading with Usana Health Sciences Inc. (USNA) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Usana Health Sciences Inc. (USNA), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies an exceptional 61.5:1 risk-reward short setup and outlines three distinct institutional trading strategies based on AI models: Position Trading, Momentum Breakout, and Risk Hedging, each with specified entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Usana Health Sciences shareholders elect board and approve auditor at annual meeting
Usana Health Sciences (NYSE:USNA) shareholders elected eight directors to its board and approved KPMG LLP as the company's independent registered public accounting firm for the 2026 fiscal year during its annual meeting. Shareholders also approved the executive compensation program on an advisory basis. The company, which recently reported strong Q1 2026 results, noted approximately 89% of issued and outstanding shares were represented at the meeting.
Usana Health Sciences shareholders elect board and approve auditor at annual meeting
Usana Health Sciences (NYSE:USNA) shareholders held their annual meeting, electing eight directors to the board, ratifying KPMG LLP as the independent auditor for fiscal year 2026, and approving the executive compensation program on an advisory basis. The company, which boasts strong gross profit margins and a healthy balance sheet, recently reported impressive financial results for Q1 2026, exceeding earnings and revenue expectations.
[8-K] USANA HEALTH SCIENCES INC Reports Material Event
USANA Health Sciences Inc. held its Annual Meeting of Shareholders on May 20, 2026, with approximately 89% of outstanding common stock represented. Shareholders elected all eight director nominees, ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026, and approved the company’s executive compensation on an advisory basis. These results indicate strong shareholder participation and support for the company's governance and compensation practices.
USANA projects $925M-$1B 2026 net sales as omnichannel mix targets over 20%
USANA Health Sciences projects net sales between $925 million and $1 billion for 2026, targeting over 20% of sales through its omnichannel strategy. The announcement indicates a strategic shift towards diversified sales channels to boost revenue growth. This outlook was shared during the company's investor day, highlighting future financial targets.
[10-Q] USANA HEALTH SCIENCES INC Quarterly Earnings Report
USANA Health Sciences Inc. (USNA) filed its Quarterly Earnings Report (10-Q) for the period ended April 4, 2026. The report details the company's financial condition, results of operations, and cash flows, highlighting a modest 0.3% increase in net sales to $250.2 million for the quarter, primarily driven by the Rise segment, despite declines in the Core Nutritional and Hiya segments. Net earnings attributable to USANA decreased by 20.1% to $7.5 million, due to a lower operating margin and higher effective tax rate.
USANA (USNA) director Peggie Pelosi awarded 6,527 restricted stock units
USANA Health Sciences director Peggie Pelosi was granted 6,527 restricted stock units (RSUs) as reported in a Form 4 filing. These RSUs represent a right to receive one share of USANA common stock each and will vest in four equal installments on specific dates in 2026 and 2027. This grant is a form of equity-based compensation and does not involve an open market purchase or sale of shares by Pelosi.
USANA (USNA) grants director 6,527 RSUs vesting through 2027
USANA Health Sciences (USNA) director John Turman Fleming has been granted 6,527 restricted stock units (RSUs). These RSUs will vest in four equal 25% installments on specific dates through April 2027, linking his compensation to the company's long-term performance and his continued service. This transaction was reported in a Form 4 filing and does not involve open-market stock sales or purchases.
USANA (USNA) director receives 6,527 restricted stock units as compensation
USANA Health Sciences director Gilbert A. Fuller was granted 6,527 restricted stock units (RSUs) on May 7, 2026, as equity-based compensation. These RSUs will vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. Each RSU represents a contingent right to receive one share of USANA common stock, reflecting compensation rather than an open-market purchase.
USANA (USNA) director J Scott Nixon awarded 6,527 restricted stock units
USANA Health Sciences director J Scott Nixon was granted 6,527 restricted stock units (RSUs). These RSUs represent a contingent right to receive one share of USANA common stock per unit and will vest in four equal installments starting July 23, 2026, and concluding April 22, 2027. This award is a routine equity-based compensation and not an open-market purchase or sale.
Director at USANA (NYSE: USNA) granted 6,527 restricted stock units
USANA Health Sciences director Timothy E. Wood was granted 6,527 restricted stock units (RSUs) in an equity award. Each RSU represents one share of USANA common stock, vesting in four equal 25% installments on specific dates between July 2026 and April 2027. After this grant, Wood directly holds 6,527 restricted stock units.
Chief Legal Officer Of USANA Health Sciences Sold 100% Of Their Shares
The Chief Legal Officer of USANA Health Sciences, P. Foukas, recently sold 100% of their holdings, netting US$75k. This insider selling, along with a significant sale by the Chief Operating Officer within the last year, raises some concerns, although insiders still own a substantial 41% of the company. No insider buying has been observed in the last year.
USANA Health Sciences (NYSE:USNA) Insider Sells $75,137.62 in Stock
USANA Health Sciences (NYSE:USNA) insider Joshua Foukas sold 3,791 shares of the company's stock on May 7th for a total value of $75,137.62. This comes after a previous sale of 4,461 shares on February 20th. Despite some negative analyst sentiment, the company beat Q1 earnings estimates and provided strong FY2026 guidance, with several institutional investors increasing their stakes.
Usana chief legal officer Joshua Foukas sells $75,137 in shares
USANA Health Sciences Inc.'s Chief Legal Officer, Joshua Foukas, sold 3,791 shares of common stock for approximately $75,137, resulting in him holding no direct shares. This transaction occurred on May 7, 2026, with the shares priced at $19.82 each. Despite the stock's recent decline, the company reported strong Q1 2026 financial results, exceeding EPS and revenue expectations.
[Form 4] USANA HEALTH SCIENCES INC Insider Trading Activity
USANA Health Sciences Inc.'s Chief Legal Officer, Joshua Foukas, reported an open-market sale of 3,791 shares of common stock at $19.82 per share on May 7, 2026. This transaction reduced his direct holdings of common stock to 0 shares. The filing indicates a net seller activity of 3,791 shares valued at $75,138.
Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
USANA Health Sciences, Inc. (NYSE:USNA) reported strong first-quarter results, with revenues surpassing estimates by 3.8% and statutory profit significantly exceeding forecasts. Despite a substantial gain in earnings per share expectations, the consensus price target for the company fell by 36% to US$39.00, indicating unresolved analyst concerns. The company is projected to grow faster in the future than in the past, though still slower than the wider industry.
Results: USANA Health Sciences, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
USANA Health Sciences, Inc. (NYSE:USNA) reported strong first-quarter results, beating revenue and profit expectations. The company's single analyst has updated forecasts, showing a substantial gain in earnings per share expectations for 2026, though the consensus price target has fallen. Despite expected improvement in revenue growth, it is still projected to be slower than the industry average, prompting caution regarding future valuation.
Usana Health Sciences Q1 Profit Rebound Tests Persistent Margin Concerns Narratives
USANA Health Sciences (USNA) reported Q1 2026 revenue of US$250.2 million and EPS of US$0.41, showing a profit rebound despite a trailing 1% net margin influenced by a one-off US$13.4 million loss. The company faces scrutiny over its high P/E ratio compared to peers and analysts expect significant earnings growth (76.9%) despite modest revenue growth (4.6%), leading to a divergence between the current share price and analyst price targets/DCF fair value. Investors are evaluating whether the recent margin performance can be sustained and if the bullish growth forecasts will materialize.
Insider files Form 144 to sell 3,791 shares (NYSE: USNA)
JOSHUA FOUKAS filed a Form 144 to report a proposed sale of 3,791 shares of USANA Health Sciences Inc. (NYSE: USNA) common stock, designated as restricted stock, with an activity date of February 27, 2026. The filing also disclosed a previous sale of 4,461 shares on February 20, 2026, which generated $95,220.05. This notice indicates an insider's intention to sell a specific amount of shares and provides transparency on past transactions.
USANA Health Sciences, Inc. (NYSE:USNA) Q1 2026 Earnings Call Transcript
USANA Health Sciences, Inc. (NYSE:USNA) reported Q1 2026 earnings, showcasing a continued transformation from a direct sales model to a diversified omni-channel health and wellness platform. The company saw sequential improvement in its core nutritional business, with net sales of $204 million, and significant growth in its omni-channel brands HYA and Rise Wellness. USANA reaffirmed its full-year 2026 guidance, projecting consolidated net sales of $925 million to $1 billion, and highlighted strategic investments in technology modernization and new product development focusing on women's and children's health, as well as active nutrition.
USANA made USA TODAY's Top Workplaces list after employee survey
USANA Health Sciences (NYSE: USNA) has been recognized on the 2026 USA TODAY Top Workplaces list, an award based on confidential employee feedback recognizing companies with strong, people-first cultures. The company was lauded for its comprehensive benefits, including onsite health and wellness amenities, competitive health insurance, wellness classes, and tuition reimbursement. This achievement underscores USANA's commitment to fostering a supportive and engaging work environment for its employees.
USANA's People-First Culture Earns Spot on USA TODAY Top Workplaces List
USANA Health Sciences Inc. (USNA) has been recognized on USA TODAY's Top Workplaces List, highlighting its people-first culture. This announcement was delivered via Quantisnow, a real-time market data and news platform. The article also provides recent analyst ratings and insider transaction data for USANA.
USANA Reports Q1 2026 Financial Results
USANA Health Sciences, Inc. announced its Q1 2026 financial results, with stable net sales at $250 million but a decrease in net earnings and diluted EPS compared to Q1 2025. The company is transitioning to a diversified, omnichannel health and wellness enterprise, with CEO Kevin Guest highlighting progress in its three segments and strong sequential growth in Greater China. USANA ended the quarter with $163 million in cash and minimal debt, providing a fiscal 2026 outlook of $925 million to $1 billion in consolidated net sales.
Usana Health Sciences Q1 2026 Earnings Call Transcript
Usana Health Sciences reported a 7% sequential growth in Q1 net sales, driven by strong customer acquisition in China and the performance of its Omnichannel brands, HAIA and Rise Wellness. The company is focusing on enhancing its Brand Partner compensation plan, accelerating new product launches, and modernizing technology to improve customer experience and drive future growth. Usana reaffirmed its full-year 2026 net sales guidance, projecting $925 million to $1 billion, with Omnichannel brands expected to contribute significantly despite higher acquisition costs and ongoing technological investments.
Earnings call transcript: USANA Health Sciences beats Q1 2026 expectations By Investing.com
USANA Health Sciences exceeded Q1 2026 earnings and revenue expectations, reporting an EPS of $0.61 against a forecast of $0.40 and revenue of $250 million versus $240.95 million. The company's stock rose by 2.6% following the announcement, driven by its strategic transformation into an omnichannel health and wellness platform and strong performance in China and new product launches across its Hiya and Rise Wellness segments. USANA reaffirmed its full-year 2026 net sales guidance, projecting $925 million to $1 billion and expects omnichannel sales to comprise over 20% of total net sales.
USANA (USNA) Q1 2026 Earnings Call Transcript
USANA Health Sciences reported a sequential improvement in net sales for Q1 2026, driven by growth in its core nutritional business and significant expansion in its HYA and Rise Wellness brands. The company is strategically diversifying into omnichannel and retail distribution, accelerating new product development, and investing in technology modernization. USANA reaffirmed its full-year 2026 guidance, expecting omnichannel revenues to comprise over 20% of total sales, and highlighted strong performance in Canada for HYA and the successful national launch of Protein Pop Plus at Costco.
USANA Health Sciences (NYSE:USNA) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS
USANA Health Sciences (NYSE:USNA) reported Q1 earnings of $0.61 per share, significantly beating the consensus estimate of $0.44. The company also exceeded revenue expectations and updated its FY 2026 EPS guidance. Despite these positive results, the stock faces downward pressure due to recent analyst downgrades, resulting in an average "Reduce" rating.
USANA Health: Q1 Earnings Snapshot
USANA Health Sciences Inc. reported a Q1 profit of $7.5 million, or 41 cents per share, with adjusted earnings of 61 cents per share. The nutritional supplement maker achieved revenue of $250.2 million for the period. The company projects full-year earnings between $1.95 and $2.29 per share and revenue ranging from $925 million to $1 billion.
USANA Health: Q1 Earnings Snapshot
USANA Health Sciences Inc. reported a profit of $7.5 million for its first quarter, with earnings of 41 cents per share, or 61 cents adjusted. The nutritional supplement maker achieved $250.2 million in revenue and anticipates full-year earnings between $1.95 and $2.29 per share, with revenue ranging from $925 million to $1 billion.
USANA Health Sciences (NYSE:USNA) - Stock Analysis
This report provides a stock analysis of USANA Health Sciences (NYSE:USNA), highlighting it as undervalued based on fair value estimates. Key points include anticipated earnings growth, analyst price targets, recent news regarding product launches and expansions into Costco, and details on its financial health and historical performance. The company develops, manufactures, and sells nutritional, personal care, and skincare products globally.
USANA Health Sciences (NYSE:USNA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded USANA Health Sciences (NYSE:USNA) from "buy" to "hold," contributing to a MarketBeat consensus rating of "Reduce." Despite beating quarterly earnings expectations with $0.60 EPS on $226.2M revenue, the company exhibited thin profitability (1.16% net margin, 6.75% ROE), and analysts project 1.95 EPS for the fiscal year. Insider transactions show a sale of 4,461 shares by Joshua Foukas, while institutional investors have adjusted their stakes in the company.
During National Show Your Smile Month, Kevin Guest Urges Leaders to Lift Others Daily
During May's National Show Your Smile Month, USANA Health Sciences Chairman and CEO Kevin Guest encourages leaders to utilize the power of a genuine smile, emphasizing its ability to lower stress, build trust, and improve communication. Guest draws on research and his book, "All the Right Reasons," to highlight how small, positive actions like smiling and showing care can foster strong relationships and drive both leadership and personal fulfillment. He advocates for treating smiling as a daily discipline, noting its significant impact on interactions and overall well-being.
A smile as a leadership tool? USANA CEO says use it under pressure
USANA Health Sciences Chairman and CEO Kevin Guest encourages leaders to use smiling as a daily discipline to reduce stress, build trust, and improve connections, especially during National Show Your Smile Month. Guest highlights lessons from his book "All the Right Reasons," which emphasizes the importance of relationships and small actions in leadership. Proceeds from his book support the USANA Foundation's hunger relief efforts, which have provided over 112 million meals and aim to feed 20,000 families by the end of 2026.
USANA Celebrates 30 Years of Excellence in Canada – Company Announcement
USANA Health Sciences is celebrating its 30th anniversary in Canada, marking three decades of growth and commitment to health and well-being in the Canadian market. Canada was USANA's first international market, and the company has highlighted its strong community, scientific products, and philanthropic impact through the USANA Foundation. USANA plans to commemorate this milestone with special events and recognition programs.
USANA Health Sciences Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics
USANA Health Sciences, a microcap player in the Pharmaceuticals & Biotechnology sector, has seen a recent valuation adjustment with a P/E ratio of 13 and a price-to-book value of 0.60. While its short-term performance is mixed, with a strong rebound over the past month, its longer-term performance lags significantly behind the broader market. Despite this, USANA presents a favorable valuation profile compared to some peers, highlighting its competitive standing.
USANA (USNA) director receives 1,057 shares from RSU vesting
USANA Health Sciences director Gilbert A. Fuller has exercised 1,057 restricted stock units (RSUs), converting them into 1,057 common shares of USANA stock with a stated price of $0.00 per share. This transaction occurred on April 23, 2026, and after it, Fuller directly holds 1,057 common shares, with no remaining RSUs from this specific grant. The RSUs vested in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA (USNA) director Peggie Pelosi exercises RSUs, with 668 shares for taxes
USANA Health Sciences director Peggie Pelosi exercised 1,057 Restricted Stock Units (RSUs) on April 23, 2026, converting them into common stock. To cover tax obligations, 668 common shares were disposed of at $19.24 per share through a tax-withholding disposition, not an open-market sale. Following these transactions, Pelosi directly holds 5,364 shares of USANA common stock.
USANA (USNA) director acquires 1,057 shares via RSU exercise
USANA Health Sciences director Frederic J Winssinger exercised 1,057 restricted stock units (RSUs) into common stock. Following this transaction, he directly holds 8,101 shares of USANA common stock. The RSUs vest in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
[Form 4] USANA HEALTH SCIENCES INC Insider Trading Activity
USANA Health Sciences director John Turman Fleming exercised 1,057 Restricted Stock Units into Common Stock on April 23, 2026. This transaction increased his direct holdings to 6,680 shares. The RSUs vested in 25% installments, with the final installment vesting and being exercised on April 23, 2026.
USANA (USNA) director Xia Ding converts RSUs and withholds 391 shares for taxes
USANA Health Sciences director Xia Ding converted 1,057 restricted stock units (RSUs) into common stock on April 23, 2026. To cover tax obligations, 391 shares were withheld and disposed of at $19.24 per share. Following these routine equity compensation transactions, Xia Ding directly holds 7,641 shares of USANA common stock.
USANA (USNA) director converts 1,057 RSUs into common stock
USANA Health Sciences director J. Scott Nixon converted 1,057 restricted stock units (RSUs) into an equal number of common shares on April 23, 2026. This transaction increased his direct holdings to 9,813 shares. The RSUs vested in four 25% installments, with the final vesting on the reported transaction date.
USANA debuts Glow, a skin capsule tied to trials in 162 women
USANA (NYSE: USNA) has launched Glow, its first ingestible skin supplement, designed to promote radiant and even-toned skin. The supplement, which contains Damasty®, astaxanthin, grape seed extract, and vitamin C, demonstrated significant improvements in skin radiance and uniformity in clinical trials involving 162 women. This launch signifies USANA's expansion into cellular-level skincare solutions, complementing its existing topical products.
USANA Health Sciences (NYSE:USNA) Lowered to "Hold" Rating by Zacks Research
Zacks Research has downgraded USANA Health Sciences (NYSE:USNA) from a "strong-buy" to a "hold" rating, reflecting mixed analyst views on the company. Despite beating Q4 EPS estimates and meeting revenue expectations, the stock, currently trading around $19, faces a "Reduce" average rating from MarketBeat data, though some institutional investors have recently increased their positions.
USANA Malaysia Launches New Vitamin D Supplement with Record-Breaking Jogging Event, Earning Malaysia Book of Records Title
USANA Malaysia launched its new Vitamin D supplement with a large-scale acupressure slow jogging event, which earned a Malaysia Book of Records title for "Most Participants in a Simultaneous Acupressure Slow Jogging Event." The event gathered over 1,000 participants and aimed to promote healthier lifestyles and raise awareness about Vitamin D deficiency in Malaysia, where over 65% of the population is deficient despite abundant sunlight. This initiative reinforces USANA's commitment to community wellness and health education.
Q3 EPS Estimates for USANA Health Sciences Cut by Sidoti
Sidoti has decreased its Q3 2026 earnings per share estimates for USANA Health Sciences (NYSE:USNA) to $0.43, down from $0.45. This comes after USANA Health Sciences outperformed previous consensus estimates in its Q4 earnings report, posting $0.60 EPS against an expected $0.41. The company's stock currently holds a "Moderate Buy" rating from analysts.
USANA Health Sciences (NYSE:USNA) Raised to "Strong-Buy" at Zacks Research
Zacks Research upgraded USANA Health Sciences (NYSE:USNA) to a "strong-buy" rating. This upgrade comes as the company continues to have mixed analyst ratings, with an overall consensus of "Moderate Buy." USANA recently beat quarterly EPS estimates and its stock currently trades around $18.50 with a market capitalization of $341.51 million.
USANA Schedules First Quarter 2026 Earnings Release and Conference Call
USANA Health Sciences, Inc. (NYSE:USNA) announced its first quarter 2026 earnings will be released on Tuesday, May 5, 2026, after market close. A Management Commentary document will be posted on their Investor Relations website, followed by a conference call for analysts and institutional investors on Wednesday, May 6, 2026, at 11:00 a.m. Eastern Time. The call will also be accessible via webcast on the company's IR website.
USANA Schedules First Quarter 2026 Earnings Release and Conference Call
USANA Health Sciences, Inc. (NYSE: USNA) announced its first-quarter 2026 earnings will be released after market close on Tuesday, May 5, 2026. A Management Commentary document will be posted on its Investor Relations website, and a conference call for analysts and institutional investors will be held the following morning, Wednesday, May 6, 2026, at 11:00 a.m. Eastern Time. USANA develops and manufactures nutritional supplements, functional foods, and personal care products, and holds ownership stakes in Hiya Health Products and Rise Wellness.
USANA Health Sciences Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics
USANA Health Sciences has adjusted its valuation, now holding a P/E ratio of 13 and a price-to-book value of 0.60. The company has shown mixed performance, outperforming the S&P 500 in the last week but experiencing declines year-to-date and over longer periods. This indicates a challenging competitive landscape within the Pharmaceuticals & Biotechnology sector for the microcap company.
USANA Health Sciences (NYSE:USNA) Stock Price
This article provides details on USANA Health Sciences (NYSE:USNA), including its stock price performance, fair value, and key financials. AnalystConsensusTarget updated a narrative highlighting share repurchases and product expansion as drivers for profitability, with a fair value of US$39, indicating the stock is 51.1% undervalued. The company manufactures and sells science-based nutritional, personal care, and skincare products globally.
